Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The FDA has approved the first once-daily protease inhibitor (PI) for the treatment of HIV-1 infections. Atazanavir (Bristol-Myers Squibb) is the newest PI to enter this relatively crowded class. It is marketed under the trade name Reyataz.

Pharmacology Update: Atazanavir Sulfate Capsules (Reyataz)